Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1973 1
1977 1
1978 1
1979 2
1982 1
1983 1
1984 2
1985 1
1986 2
1987 3
1988 4
1989 3
1990 3
1991 3
1992 2
1993 14
1994 10
1995 4
1996 8
1998 6
1999 6
2000 11
2001 5
2002 3
2003 6
2004 4
2005 3
2006 3
2007 3
2008 2
2009 3
2010 1
2011 3
2012 7
2013 7
2014 5
2015 5
2016 11
2017 13
2018 19
2019 10
2020 20
2021 26
2022 17
2023 16
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, Mitani H, Iwae S, Fujimoto Y, Onozawa Y, Hanai N, Ogawa T, Hara H, Monden N, Shimura E, Minami S, Fujii T, Tanaka K, Homma A, Yoshimoto S, Oridate N, Omori K, Ueda T, Okami K, Ota I, Shiga K, Sugasawa M, Asakage T, Saito Y, Murono S, Nishimura Y, Nakamura K, Hayashi R; Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG). Kiyota N, et al. Among authors: hanai n. J Clin Oncol. 2022 Jun 20;40(18):1980-1990. doi: 10.1200/JCO.21.01293. Epub 2022 Mar 1. J Clin Oncol. 2022. PMID: 35230884 Free PMC article. Clinical Trial.
Human papillomavirus-related oropharyngeal carcinoma.
Saito Y, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ota I, Yokota T, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Okano S, Imamura Y, Ariizumi Y, Hayashi R. Saito Y, et al. Among authors: hanai n. Jpn J Clin Oncol. 2022 Jul 8;52(7):700-706. doi: 10.1093/jjco/hyac049. Jpn J Clin Oncol. 2022. PMID: 35383359 Review.
Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer.
Nishikawa D, Suzuki H, Beppu S, Terada H, Sawabe M, Hanai N. Nishikawa D, et al. Among authors: hanai n. Cancers (Basel). 2022 Nov 17;14(22):5662. doi: 10.3390/cancers14225662. Cancers (Basel). 2022. PMID: 36428754 Free PMC article. Review.
Current topics and management of head and neck sarcomas.
Kobayashi K, Hanai N, Yoshimoto S, Saito Y, Homma A. Kobayashi K, et al. Among authors: hanai n. Jpn J Clin Oncol. 2023 Aug 30;53(9):743-756. doi: 10.1093/jjco/hyad048. Jpn J Clin Oncol. 2023. PMID: 37309253 Free PMC article. Review.
Prognostic scores for patients with salivary adenoid cystic carcinoma without lymph node metastasis.
Shimoda H, Teshima M, Murase T, Nagao T, Kusafuka K, Nakaguro M, Urano M, Taguchi KI, Yamamoto H, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Kawakita D, Sakurai K, Hanai N, Nagao T, Kawata R, Hato N, Nibu KI, Inagaki H. Shimoda H, et al. Among authors: hanai n. Oral Oncol. 2023 Oct;145:106491. doi: 10.1016/j.oraloncology.2023.106491. Epub 2023 Jul 22. Oral Oncol. 2023. PMID: 37487445
The Landscape of MYB/MYBL1- and Peri-MYB/MYBL1-Associated Rearrangements in Adenoid Cystic Carcinoma.
Ueda K, Murase T, Kawakita D, Nagao T, Kusafuka K, Nakaguro M, Urano M, Yamamoto H, Taguchi KI, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Sakurai K, Hanai N, Nagao T, Kawata R, Hato N, Nibu KI, Inagaki H. Ueda K, et al. Among authors: hanai n. Mod Pathol. 2023 Oct;36(10):100274. doi: 10.1016/j.modpat.2023.100274. Epub 2023 Jul 7. Mod Pathol. 2023. PMID: 37423587
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Takahashi S, Oridate N, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, Yokota T, Yamazaki T, Takahashi M, Ueda T, Hanai N, Yamaguchi H, Hara H, Yoshizaki T, Yasumatsu R, Nakayama M, Shiga K, Fujii T, Mitsugi K, Takahashi K, Nohata N, Gumuscu B, Swaby RF, Tahara M. Takahashi S, et al. Among authors: hanai n. Int J Clin Oncol. 2022 Dec;27(12):1805-1817. doi: 10.1007/s10147-022-02233-6. Epub 2022 Oct 20. Int J Clin Oncol. 2022. PMID: 36264378 Free PMC article. Clinical Trial.
Immunotherapy for squamous cell carcinoma of the head and neck.
Yokota T, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Okano S, Imamura Y, Ariizumi Y, Hayashi R; Japan Clinical Oncology Group (JCOG) Head and Neck Cancer Study Group. Yokota T, et al. Among authors: hanai n. Jpn J Clin Oncol. 2020 Sep 28;50(10):1089-1096. doi: 10.1093/jjco/hyaa139. Jpn J Clin Oncol. 2020. PMID: 32776100 Review.
258 results